Message Center
{{ messageCount }} Messages
Watched Genes
{{$index + 1}}. {{ watchedObject.symbol }} (RGD ID:{{watchedObject.rgdId}})
Watched Ontology Terms
{{$index + 1}}. {{ watchedTerm.term }} ({{watchedTerm.accId}})
{{gene.symbol}}: {{ gene.description }}
Save what matters to you
{{ loginError }}
Sign in with your RGD account
Gene: Ubr1 (ubiquitin protein ligase E3 component n-recognin 1) Rattus norvegicus
Analyze
Symbol:
Ubr1
Name:
ubiquitin protein ligase E3 component n-recognin 1
RGD ID:
1562326
Description:
Predicted to have leucine binding activity and ubiquitin-protein transferase activity. Predicted to be involved in cellular response to leucine; negative regulation of TOR signaling; and ubiquitin-dependent protein catabolic process. Predicted to localize to proteasome complex and ubiquitin ligase complex. Human ortholog(s) of this gene implicated in Johanson-Blizzard syndrome. Orthologous to human UBR1 (ubiquitin protein ligase E3 component n-recognin 1); INTERACTS WITH 17alpha-ethynylestradiol; 2,3,7,8-tetrachlorodibenzodioxine; bisphenol A.
Type:
protein-coding
RefSeq Status:
PROVISIONAL
Also known as:
E3 ubiquitin-protein ligase UBR1; LOC499877; RGD1562326; similar to ubiquitin-protein ligase E3-alpha
RGD Orthologs
Alliance Genes
More Info
more info ...
More Info
Latest Assembly:
Rnor_6.0 - RGSC Genome Assembly v6.0
NCBI Annotation Information:
Annotation category: partial on reference assembly
Position:
Rat Assembly Chr Position (strand) Source Genome Browsers JBrowse NCBI UCSC Ensembl Rnor_6.0 3 112,800,557 - 112,910,038 (-) NCBI Rnor6.0 Rnor_6.0 rn6 Rnor6.0 Rnor_6.0 Ensembl 3 112,800,557 - 112,876,773 (-) Ensembl Rnor6.0 rn6 Rnor6.0 Rnor_5.0 3 119,343,521 - 119,453,073 (-) NCBI Rnor5.0 Rnor_5.0 rn5 Rnor5.0 RGSC_v3.4 3 107,632,668 - 107,746,611 (-) NCBI RGSC3.4 rn4 RGSC3.4 Celera 3 106,718,636 - 106,826,666 (-) NCBI Celera Cytogenetic Map 3 q35 NCBI
JBrowse:
View Region in Genome Browser (JBrowse)
Model
Imported Disease Annotations - ClinVar
Imported Disease Annotations - OMIM
(-)-epigallocatechin 3-gallate multiple interactions ISO RGD:1347280 6480464 [potassium chromateVI co-treated with epigallocatechin gallate] results in decreased expression of UBR1 mRNA CTD PMID:22079256 17alpha-ethynylestradiol increases expression EXP 6480464 Ethinyl Estradiol results in increased expression of UBR1 mRNA CTD PMID:29097150 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:1623272 6480464 Tetrachlorodibenzodioxin affects the expression of UBR1 mRNA CTD PMID:21570461 2,3,7,8-tetrachlorodibenzodioxine increases expression EXP 6480464 Tetrachlorodibenzodioxin results in increased expression of UBR1 mRNA CTD PMID:32109520 2-hydroxypropanoic acid decreases expression ISO RGD:1347280 6480464 Lactic Acid results in decreased expression of UBR1 mRNA CTD PMID:30851411 3-isobutyl-1-methyl-7H-xanthine multiple interactions ISO RGD:1347280 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of UBR1 mRNA CTD PMID:28628672 4,4'-diaminodiphenylmethane increases expression ISO RGD:1623272 6480464 4, 4'-diaminodiphenylmethane results in increased expression of UBR1 mRNA CTD PMID:18648102 aflatoxin B1 increases expression ISO RGD:1347280 6480464 Aflatoxin B1 results in increased expression of UBR1 mRNA CTD PMID:21641981 aflatoxin B1 increases expression ISO RGD:1623272 6480464 Aflatoxin B1 results in increased expression of UBR1 mRNA CTD PMID:19770486 aflatoxin B2 decreases methylation ISO RGD:1347280 6480464 aflatoxin B2 results in decreased methylation of UBR1 intron CTD PMID:30157460 benzo[a]pyrene increases expression ISO RGD:1347280 6480464 Benzoapyrene results in increased expression of UBR1 mRNA CTD PMID:21871943 benzo[a]pyrene increases methylation ISO RGD:1623272 6480464 Benzoapyrene results in increased methylation of UBR1 exon, Benzoapyrene results in increased methylation of UBR1 intron CTD PMID:27901495 benzo[a]pyrene affects methylation ISO RGD:1347280 6480464 Benzoapyrene affects the methylation of UBR1 intron CTD PMID:30157460 benzo[a]pyrene increases methylation ISO RGD:1347280 6480464 Benzoapyrene results in increased methylation of UBR1 promoter CTD PMID:27901495 benzo[a]pyrene diol epoxide I decreases expression ISO RGD:1347280 6480464 7 more ... CTD PMID:19150397 benzo[e]pyrene decreases methylation ISO RGD:1347280 6480464 benzoepyrene results in decreased methylation of UBR1 intron CTD PMID:30157460 bisphenol A increases expression EXP 6480464 bisphenol A results in increased expression of UBR1 mRNA CTD PMID:25181051 , PMID:29097150 bisphenol A multiple interactions EXP 6480464 [bisphenol A co-treated with tributyltin] results in decreased expression of UBR1 mRNA CTD PMID:31129395 bisphenol A decreases expression EXP 6480464 bisphenol A results in decreased expression of UBR1 mRNA CTD PMID:30816183 bisphenol A multiple interactions ISO RGD:1347280 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of UBR1 mRNA CTD PMID:28628672 bisphenol A increases methylation EXP 6480464 bisphenol A results in increased methylation of UBR1 gene CTD PMID:28505145 choline multiple interactions ISO RGD:1623272 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of UBR1 gene CTD PMID:20938992 chromium(6+) decreases expression ISO RGD:1347280 6480464 chromium hexavalent ion results in decreased expression of UBR1 mRNA CTD PMID:30690063 dexamethasone multiple interactions ISO RGD:1347280 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of UBR1 mRNA CTD PMID:28628672 dicrotophos decreases expression ISO RGD:1347280 6480464 dicrotophos results in decreased expression of UBR1 mRNA CTD PMID:28302478 doxorubicin decreases expression ISO RGD:1347280 6480464 Doxorubicin results in decreased expression of UBR1 mRNA CTD PMID:29803840 folic acid multiple interactions ISO RGD:1623272 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of UBR1 gene CTD PMID:20938992 hydrogen peroxide affects expression ISO RGD:1347280 6480464 Hydrogen Peroxide affects the expression of UBR1 mRNA CTD PMID:20044591 indometacin multiple interactions ISO RGD:1347280 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of UBR1 mRNA CTD PMID:28628672 L-methionine multiple interactions ISO RGD:1623272 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of UBR1 gene CTD PMID:20938992 methapyrilene decreases methylation ISO RGD:1347280 6480464 Methapyrilene results in decreased methylation of UBR1 intron CTD PMID:30157460 methapyrilene decreases expression EXP 6480464 Methapyrilene results in decreased expression of UBR1 mRNA CTD PMID:30467583 methyl methanesulfonate increases expression ISO RGD:1347280 6480464 Methyl Methanesulfonate results in increased expression of UBR1 mRNA CTD PMID:23649840 N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal increases expression ISO RGD:1623272 6480464 benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of UBR1 mRNA CTD PMID:20061341 nickel atom increases expression ISO RGD:1347280 6480464 Nickel results in increased expression of UBR1 mRNA CTD PMID:25583101 oxaliplatin multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in decreased expression of UBR1 mRNA CTD PMID:25729387 paracetamol decreases expression ISO RGD:1347280 6480464 Acetaminophen results in decreased expression of UBR1 mRNA CTD PMID:21420995 phenytoin increases expression EXP 6480464 Phenytoin results in increased expression of UBR1 mRNA CTD PMID:20345932 poly(I:C) multiple interactions EXP 6480464 [Poly I-C co-treated with HU 211] results in decreased expression of UBR1 mRNA CTD PMID:26923065 potassium chromate multiple interactions ISO RGD:1347280 6480464 [potassium chromateVI co-treated with epigallocatechin gallate] results in decreased expression of UBR1 mRNA CTD PMID:22079256 potassium chromate decreases expression ISO RGD:1347280 6480464 potassium chromateVI results in decreased expression of UBR1 mRNA CTD PMID:22079256 , PMID:22714537 rac-lactic acid decreases expression ISO RGD:1347280 6480464 Lactic Acid results in decreased expression of UBR1 mRNA CTD PMID:30851411 sodium arsenite increases expression ISO RGD:1347280 6480464 sodium arsenite results in increased expression of UBR1 mRNA CTD PMID:20886546 thapsigargin increases expression ISO RGD:1623272 6480464 Thapsigargin results in increased expression of UBR1 protein CTD PMID:24648495 thimerosal increases expression ISO RGD:1347280 6480464 Thimerosal results in increased expression of UBR1 mRNA CTD PMID:27188386 topotecan decreases expression EXP 6480464 Topotecan results in decreased expression of UBR1 mRNA CTD PMID:25729387 topotecan multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in decreased expression of UBR1 mRNA CTD PMID:25729387 tributylstannane multiple interactions EXP 6480464 [bisphenol A co-treated with tributyltin] results in decreased expression of UBR1 mRNA CTD PMID:31129395 trichostatin A decreases expression ISO RGD:1347280 6480464 trichostatin A results in decreased expression of UBR1 mRNA CTD PMID:24935251 valproic acid affects expression ISO RGD:1623272 6480464 Valproic Acid affects the expression of UBR1 mRNA CTD PMID:17292431 valproic acid affects splicing EXP 6480464 Valproic Acid affects the splicing of UBR1 mRNA CTD PMID:29427782
References
Additional References at PubMed
Genomics
QTLs in Region (Rnor_6.0)
1358885 Bp251 Blood pressure QTL 251 3.8 arterial blood pressure trait (VT:2000000) mean arterial blood pressure (CMO:0000009) 3 10639528 127023997 Rat 1358888 Bp264 Blood pressure QTL 264 4.43 arterial blood pressure trait (VT:2000000) mean arterial blood pressure (CMO:0000009) 3 10639528 127023997 Rat 737818 Hcar12 Hepatocarcinoma resistance QTL 12 2.6 liver integrity trait (VT:0010547) volume of individual liver tumorous lesion (CMO:0001078) 3 30114912 123700444 Rat 70216 Cm14 Cardiac mass QTL 14 2.1 heart mass (VT:0007028) heart wet weight (CMO:0000069) 3 30846101 172879276 Rat 1358362 Srcrt2 Stress Responsive Cort QTL 2 2.78 blood corticosterone amount (VT:0005345) plasma corticosterone level (CMO:0001173) 3 39248391 140271184 Rat 2301970 Bw81 Body weight QTL 81 5.19 body mass (VT:0001259) body weight (CMO:0000012) 3 43295930 163640485 Rat 2301971 Cm71 Cardiac mass QTL 71 4.63 heart left ventricle mass (VT:0007031) heart left ventricle weight (CMO:0000776) 3 43295930 163640485 Rat 1581503 Cm58 Cardiac mass QTL 58 2.7 0.05 heart left ventricle mass (VT:0007031) heart left ventricle weight to body weight ratio (CMO:0000530) 3 45406058 127023997 Rat 1559282 Emca5 Estrogen-induced mammary cancer QTL 5 3.9 mammary gland integrity trait (VT:0010552) percentage of study population developing mammary tumors during a period of time (CMO:0000948) 3 45406058 177699992 Rat 2292591 Esta4 Estrogen-induced thymic atrophy QTL 4 thymus mass (VT:0004954) thymus wet weight (CMO:0000855) 3 48561928 155263151 Rat 1358186 Ept2 Estrogen-induced pituitary tumorigenesis QTL 2 8.3 pituitary gland mass (VT:0010496) pituitary gland wet weight (CMO:0000853) 3 48562146 115249962 Rat 2292613 Ept16 Estrogen-induced pituitary tumorigenesis QTL 16 8.3 pituitary gland mass (VT:0010496) pituitary gland wet weight (CMO:0000853) 3 48562146 115249962 Rat 631665 Bw8 Body weight QTL 8 5.5 body mass (VT:0001259) body weight (CMO:0000012) 3 51821836 124513579 Rat 724523 Tsu1 Thymus enlargement suppressive QTL 1 3.84 thymus mass (VT:0004954) thymus weight to body weight ratio (CMO:0000612) 3 51822008 120917851 Rat 1582218 Bw74 Body weight QTL 74 3.9 0.0021 body mass (VT:0001259) body weight (CMO:0000012) 3 54630948 119830094 Rat 1582238 Bw68 Body weight QTL 68 3.2 0.0064 body mass (VT:0001259) body weight (CMO:0000012) 3 54630948 119830094 Rat 1582239 Epfw1 Epididymal fat weight QTL 1 4.5 0.0006 epididymal fat pad mass (VT:0010421) epididymal fat pad weight to body weight ratio (CMO:0000658) 3 54630948 119830094 Rat 1581568 Rf53 Renal function QTL 53 total urine protein amount (VT:0000032) urine protein excretion rate to body weight ratio (CMO:0001099) 3 58204463 170534769 Rat 8662816 Vetf4 Vascular elastic tissue fragility QTL 4 4 renal artery integrity trait (VT:0010642) number of ruptures of the internal elastic lamina of the renal arteries (CMO:0002563) 3 61241033 165369047 Rat 1300111 Rf12 Renal function QTL 12 3.78 renal blood flow trait (VT:2000006) absolute change in renal blood flow rate (CMO:0001168) 3 62922868 127023997 Rat 1582221 Kidm30 Kidney mass QTL 30 3.5 0.0008 kidney mass (VT:0002707) both kidneys wet weight (CMO:0000085) 3 66711607 119830094 Rat 1582210 Bw71 Body weight QTL 71 3.3 0.0012 body mass (VT:0001259) body weight (CMO:0000012) 3 66711607 119830094 Rat 12879848 Bw181 Body weght QTL 181 0.015 body mass (VT:0001259) body weight (CMO:0000012) 3 72672290 127023997 Rat 2301414 Kidm37 Kidney mass QTL 37 0.001 kidney mass (VT:0002707) both kidneys wet weight to body weight ratio (CMO:0000340) 3 72973445 127023997 Rat 1600376 Arunc5 Aerobic running capacity QTL 5 0.21 exercise endurance trait (VT:0002332) maximum distance run on treadmill (CMO:0001406) 3 78700444 123700444 Rat 1581546 Pur13 Proteinuria QTL 13 2.93 0.0335 total urine protein amount (VT:0000032) urine protein excretion rate (CMO:0000759) 3 81136227 154416635 Rat 2302273 Gluco35 Glucose level QTL 35 5.3 0.001 blood glucose amount (VT:0000188) blood glucose level (CMO:0000046) 3 83817637 119509260 Rat 7387306 Bw124 Body weight QTL 124 3.2 0.0003 body mass (VT:0001259) body weight (CMO:0000012) 3 88910015 133910015 Rat 631649 Bp123 Blood pressure QTL 123 3.2 arterial blood pressure trait (VT:2000000) systolic blood pressure (CMO:0000004) 3 94788365 139788365 Rat 8694437 Bw167 Body weight QTL 167 22.46 0.001 retroperitoneal fat pad mass (VT:0010430) retroperitoneal fat pad weight to body weight ratio (CMO:0000635) 3 97009185 142009185 Rat 631841 Niddm39 Non-insulin dependent diabetes mellitus QTL 39 3.36 blood glucose amount (VT:0000188) blood glucose level (CMO:0000046) 3 99465522 168732722 Rat 1582219 Bw63 Body weight QTL 63 3.8 0.001 body mass (VT:0001259) body weight (CMO:0000012) 3 100730984 119830094 Rat 724532 Cm17 Cardiac mass QTL 17 2 heart mass (VT:0007028) calculated heart weight (CMO:0000073) 3 101058963 146058963 Rat 2293087 Iddm27 Insulin dependent diabetes mellitus QTL 27 2.68 blood glucose amount (VT:0000188) blood glucose level (CMO:0000046) 3 102152812 155263151 Rat 1354611 Despr2 Despair related QTL 2 3.03 0.0028 locomotor behavior trait (VT:0001392) amount of time spent in voluntary immobility (CMO:0001043) 3 102466149 147466149 Rat 2312659 Slep7 Serum leptin concentration QTL 7 0.001 blood leptin amount (VT:0005667) serum leptin level (CMO:0000780) 3 103141814 176418101 Rat 2312670 Bw94 Body weight QTL 94 0.01 inguinal fat pad mass (VT:0010424) inguinal fat pad weight to body weight ratio (CMO:0001253) 3 103141814 176418101 Rat 2312673 Scl63 Serum cholesterol level QTL 63 0.001 blood cholesterol amount (VT:0000180) serum total cholesterol level (CMO:0000363) 3 103141814 176418101 Rat 2302373 Gluco39 Glucose level QTL 39 5.01 blood glucose amount (VT:0000188) blood glucose level area under curve (AUC) (CMO:0000350) 3 103141944 170934860 Rat 1582216 Bw65 Body weight QTL 65 6.3 body mass (VT:0001259) body weight (CMO:0000012) 3 106900427 119830094 Rat
